Iclusig
(i-KLOO-sig)
A drug used alone or with other drugs to treat adults with certain types of chronic myelogenous leukemia or Philadelphia chromosome–positive acute lymphoblastic leukemia. It is used in patients whose cancer is newly diagnosed, has the T315I mutation, or cannot be treated with other kinase inhibitors. It is also being studied in the treatment of other types of cancer. Iclusig blocks BCR::ABL1 and other proteins, which may help keep cancer cells from growing and may kill them. It may also prevent the growth of new blood vessels that tumors need to grow. Iclusig is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called ponatinib hydrochloride.